“To examine whether detoxifying patients with medication-overuse headache can reduce long-term medication costs. Direct costs of medications in medication-overuse headache have been reported to be very high but have never been calculated on the basis of exact register data. Long-term economic savings obtained by detoxification have never been investigated. We conducted a registry-based observational retrospective follow-up
study on 336 medication-overuse headache patients treated and discharged from the Danish Headache Center over a 2-year period. By means of the Danish Register of Medicinal Product Statistics, we collected information Talazoparib mw on the costs and use of prescription-only medication 1 year before admission and 1 year after discharge from Danish Headache Center. The average medication costs per patient per year decreased with 24%, from US$971 before treatment to US$737 after (P = .001), and the average medication use decreased with 14.4% (P = .02). Savings were most pronounced for patients overusing triptans. In this group, the average medication costs per patient per year decreased with 43% (P < .001), while the average triptan use decreased with 38% (P < .001). The study Roxadustat clinical trial demonstrates that detoxification of medication-overuse headache at a tertiary headache center has a long-lasting effect on the medication costs and use, in
particular among patients overusing triptans. The results may not be generalizable to all countries and may be sensitive to the costs of triptans. “
“Background.— Spinal manipulation (SM) is a therapy which is frequently used for headaches. During the last decade, several systematic reviews (SRs) of this topic have been published. Confusingly, their conclusions are far from uniform. The aim of this article is to identify the reasons for MCE this confusion and to create more clarity about the therapeutic value of SM. Methods.— SRs were identified through searches of Medline, Embase, Cochrane Library, Amed, Cinahl,
and PsychInfo. They were considered if they were recent, systematic, and evaluated the effectiveness of SM for headache disorders. Results.— Six SRs were included. Their methodological quality was assessed using the Oxman criteria for SRs. Five SRs were of high quality and one was associated with a high risk of bias. The findings of the SRs differed considerably. This variance seemed to be caused by several factors: differences in conditions included, treatments assessed, or primary studies analyzed. Conclusion.— We conclude that high-quality SRs with a clear focus are required before the value of SM for headaches can be defined. “
“(Headache 2010;50:219-223) Objective.— To evaluate the effectiveness of nonpharmacologic treatment for migraine in children younger than age 6 years. Background.— The mean age of onset of migraine in children is 7.2 years for boys and 10.9 years for girls.